● neutral
Impact
PhasePhase 2b
Time to marketIf the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.
olevaprubart Updated Nov 12
What to watch
The next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.
Bull case
- Olevaprubart is a potential first-in-class non-T cell-depleting, ADCC-silenced anti-OX40 antagonist with an extended half-life, which could offer a differentiated safety and dosing profile versus competitors like rocatinlimab (T-cell depleting).
- Phase 2a data in atopic dermatitis showed rapid, marked, and durable improvement with a well-tolerated profile and no Kaposi sarcoma cases across all trials, addressing a key safety concern for the class.
- Sanofi's abandonment of amlitelimab and AbCellera's OX40 exit reduce competitive noise, potentially widening olevaprubart's commercial opportunity if Phase 2b succeeds.
Bear case
- The Phase 2b ADAPTIVE topline readout is not expected until Q4 2027, leaving the stock without a near-term binary catalyst for over a year, which creates a long period of data-free drift.
- The OX40 class is crowded and has seen setbacks: Sanofi abandoned amlitelimab approval efforts in atopic dermatitis (July 2026), and AbCellera exited the space (Nov 2026), raising questions about the commercial viability of the mechanism.
- Rocatinlimab (Amgen/Kyowa Kirin) has already reported positive Phase 3 ROCKET data, potentially establishing a competitive benchmark that olevaprubart must match or exceed.